A Wegovy prescription doesn't guarantee your insurance company will pay for it. Wegovy is a higher-dose formulation of semaglutide, the same active ingredient found in Ozempic, but it is FDA-approved specifically for chronic weight management and, in some patients, for reducing the risk of major cardiovascular events. Because of this, insurers evaluate Wegovy requests differently than they evaluate diabetes medications.
Before approving coverage, most plans require a prior authorization review. This process checks whether your BMI, health history, and previous treatment attempts meet the plan's clinical policy for weight management drugs, which are traditionally scrutinized more closely than most other prescription categories.
Knowing what your insurer looks for before your provider submits the paperwork can prevent weeks of delay. It also helps you and your provider assemble the right documentation the first time, instead of waiting for the insurer to request it after an initial denial.
Table of Contents
- Common Wegovy Prior Authorization Requirements
- Commercial Insurance vs Medicare vs Medicaid
- BMI & Comorbidity Criteria
- Step Therapy Requirements
- Required Clinical Documentation
- Quantity Limits & Dose Titration
- What Happens During Review
- Reasons Prior Authorizations Are Denied
- How to Appeal a Denial
- Alternatives if Coverage Is Refused
- Frequently Asked Questions
Common Wegovy Prior Authorization Requirements
Wegovy's clinical policies tend to be stricter than those for diabetes medications like Ozempic, because weight management drugs historically carry higher scrutiny and cost pressure for payers. Most requests are evaluated against the same core factors.
| Requirement | Common Requirement | Purpose |
|---|---|---|
| BMI Threshold | ≥30, or ≥27 with a comorbidity | Matches FDA-approved indication |
| Weight History | Documented weight over time | Confirms chronic weight issue, not short-term fluctuation |
| Step Therapy | Diet/exercise program or prior weight-loss medication | Shows lower-cost options were attempted first |
| Medical Records | Progress notes, comorbidity diagnoses | Supports medical necessity |
| Prescription Limits | One pen carton per 28-day supply | Prevents excessive dispensing |
Because Wegovy's monthly cost is high, insurers tend to scrutinize weight-history documentation closely. Submitting several months of tracked weight, along with a clear comorbidity diagnosis where applicable, is one of the most effective ways to avoid a first-round denial.
Commercial Insurance vs Medicare vs Medicaid
Coverage for Wegovy varies more by payer type than coverage for diabetes drugs does, largely because federal rules historically excluded weight-loss drugs from Medicare Part D. That has changed only in narrow circumstances.
| Insurance | Typical Coverage | Prior Authorization | Common Requirement |
|---|---|---|---|
| Commercial Insurance | Plan Dependent | Usually Required | BMI + Step Therapy |
| Medicare Part D | Cardiovascular Risk Only | Frequently Required | Established Heart Disease Diagnosis |
| Medicaid | Varies By State | Usually Required | State Clinical Criteria |
Important: Employer-sponsored plans frequently exclude weight-loss drugs entirely, regardless of what the insurance carrier's standard policy says. Always check your specific plan document, not just the carrier name.
BMI and Comorbidity Criteria
Unlike Ozempic, Wegovy approval hinges almost entirely on BMI and weight-related health conditions rather than a diabetes diagnosis, since Wegovy's core indication is chronic weight management.
| Clinical Factor | Common Requirement | Importance |
|---|---|---|
| BMI ≥30 | Usually Sufficient Alone | Very High |
| BMI ≥27 + Comorbidity | Common Alternate Pathway | Very High |
| Hypertension | Accepted Comorbidity | High |
| Type 2 Diabetes | Accepted Comorbidity | High |
| High Cholesterol / Dyslipidemia | Accepted Comorbidity | Moderate |
| Established Cardiovascular Disease | Required for Medicare Coverage | Very High (Medicare Only) |
BMI alone isn't always enough. Some plans still require a comorbidity even at BMI 30+, and nearly all plans require documented weight over time rather than a single office visit measurement. A single high BMI reading without supporting history is a common reason for delay.
Step Therapy Requirements
Many insurers apply step therapy to Wegovy, requiring documentation of prior weight-management attempts before approving a GLP-1 medication. This can include structured diet and exercise programs, behavioral counseling, or trials of other weight-loss medications.
| Prior Requirement | Frequently Required? | Reason |
|---|---|---|
| Documented diet/exercise program (3-6 months) | Yes | Confirms lifestyle measures were tried |
| Phentermine-topiramate (Qsymia) | Sometimes | Lower-cost oral alternative |
| Naltrexone-bupropion (Contrave) | Sometimes | Lower-cost oral alternative |
| Liraglutide (Saxenda) | Some plans | Same drug class, lower cost in some formularies |
When Step Therapy Can Be Waived
Insurers may bypass step therapy requirements when your healthcare provider documents a valid clinical reason, such as:
- Previous intolerance to another weight-loss medication.
- Contraindications to alternative therapies.
- Severe comorbidities that make delaying treatment risky.
- Documented allergy to an alternative medication.
- Previous treatment failure despite adequate duration and dosing.
Submitting this documentation with the initial request is usually faster than waiting for a denial and filing an appeal afterward.
Required Clinical Documentation
Most insurers ask providers to submit specific supporting records alongside the prior authorization form. Missing documentation is one of the most common reasons Wegovy requests stall.
| Document | Usually Requested |
|---|---|
| Height and Weight History | Yes |
| Calculated BMI | Yes |
| Comorbidity Diagnosis (if applicable) | Yes |
| Diet/Exercise Program Documentation | Yes |
| Previous Weight-Loss Medication History | Often |
| Cardiovascular Disease Diagnosis (Medicare only) | Medicare Only |
Example Prior Authorization Timeline
Prescription Written
Your healthcare provider prescribes Wegovy and sends the prescription to your pharmacy.
Insurance Requests Prior Authorization
The pharmacy notifies your healthcare provider that approval is required before the prescription can be filled.
Provider Submits Documentation
Your provider submits BMI records, weight history, comorbidity diagnoses and any additional documentation the insurer requests.
Clinical Review
The insurer reviews the submitted documentation against its weight-management drug policy and formulary requirements.
Approval or Denial
If approved, the pharmacy processes the prescription. If denied, the insurer provides the reason and appeal instructions.
Quantity Limits and Dose Titration
Wegovy is dispensed on a titration schedule that gradually increases the dose over several months. Insurers typically apply quantity limits matched to this schedule.
| Limit | Typical Policy |
|---|---|
| Standard Quantity | 1 carton (4 pens) every 28 days |
| Dose Titration | 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over ~16-20 weeks |
| Early Refills | Usually Restricted |
| Maintenance Dose Renewal | Often Requires Progress Documentation |
Some plans require documented weight-loss progress, typically 5% or more of baseline body weight, at renewal checkpoints (often 3, 6, or 12 months) to continue coverage at the maintenance dose.
Common Reasons Wegovy Prior Authorization Is Denied
A denial doesn't necessarily mean your plan will never cover Wegovy. Many denials happen because required documentation is incomplete or because the insurer's specific weight-management criteria haven't been demonstrated yet.
| Reason for Denial | What It Means | Possible Solution |
|---|---|---|
| BMI below plan threshold | Documented BMI doesn't meet the 30, or 27-with-comorbidity, standard. | Submit updated height/weight records and any qualifying comorbidity. |
| No documented weight-management attempt | Plan requires evidence of diet, exercise, or prior medication. | Document a structured program or note contraindications to alternatives. |
| Missing comorbidity diagnosis | BMI is below 30 and no qualifying condition is documented. | Submit diagnosis codes for hypertension, diabetes, or dyslipidemia if present. |
| Plan excludes weight-loss drugs | Employer or plan design excludes the entire drug category. | Check plan documents; consider appeal or alternative coverage pathway. |
| Medicare without cardiovascular indication | Medicare Part D generally does not cover weight loss alone. | Discuss whether a cardiovascular risk-reduction diagnosis applies. |
Decision Tree: What Should You Do Next?
Step 1: Is your BMI 30 or higher, or 27+ with a qualifying condition?
✔ Yes → Continue to Step 2.
✖ No → Your insurer will likely deny coverage. Discuss lifestyle programs or lower-BMI-eligible options with your provider.
Step 2: Have you documented a prior weight-management attempt if your plan requires step therapy?
✔ Yes → Continue to Step 3.
✖ No → Your insurer may require this documentation before approving Wegovy.
Step 3: Do you have Medicare, and is Wegovy being prescribed for weight loss alone?
✔ No (commercial/Medicaid, or Medicare with cardiovascular disease) → Wait for the insurer's review.
✖ Yes (Medicare, weight loss only) → Medicare Part D generally will not cover this use; ask your provider about alternative pathways.
How to Appeal a Wegovy Prior Authorization Denial
Many denied Wegovy requests are approved after additional documentation is submitted. An appeal gives your healthcare provider the opportunity to demonstrate why Wegovy is medically necessary for your specific case.
Read the denial letter carefully
Review the specific reason listed by the insurer, whether it's BMI, missing documentation, or a plan exclusion.
Contact your healthcare provider
Share the denial letter so your provider can determine what additional records or explanation are needed.
Submit supporting evidence
Appeals often include updated weight records, comorbidity diagnoses, documented lifestyle interventions, and a letter of medical necessity.
Follow up with your insurer
Many insurers let patients and providers check appeal status online or by phone while the review is underway.
Need help understanding the appeal process? Read our complete guide: How to Appeal a Prescription Denial.
Alternatives If Wegovy Is Not Covered
If your insurer denies Wegovy, your healthcare provider may recommend a different medication that better matches your formulary or clinical profile.
| Medication | Primary Use | Insurance Coverage |
|---|---|---|
| Wegovy | Chronic Weight Management | Plan Dependent |
| Zepbound | Weight Management | Growing Coverage |
| Saxenda | Chronic Weight Management | Some Commercial Plans |
| Ozempic (off-label) | Type 2 Diabetes (used off-label for weight) | Usually Requires Diabetes Diagnosis |
| Qsymia / Contrave | Weight Management (oral) | More Commonly Covered |
If you have Medicare and don't qualify for Wegovy coverage under the cardiovascular risk pathway, it may help to learn whether the Medicare GLP-1 Bridge Program offers another route for eligible beneficiaries.
How Prior Authorization Requirements Differ by Insurance Company
Every insurer sets its own clinical policy, formulary placement, and documentation requirements for Wegovy. Two patients with identical BMI and health history may receive different coverage decisions simply because they have different plans.
Employer-sponsored plans in particular often add exclusions or additional requirements for weight-management drugs beyond what the insurance carrier's standard policy states. Always treat prior authorization requirements as plan-specific.
| Insurance Company | Prior Authorization | Step Therapy | Typical Documentation |
|---|---|---|---|
| Aetna | Usually Required | Common | BMI, comorbidity, weight history |
| Blue Cross Blue Shield | Varies by plan | Often | Clinical notes and weight-management history |
| UnitedHealthcare | Usually Required | Common | Provider documentation and BMI records |
| Cigna | Usually Required | Often | Diagnosis codes and previous weight-loss attempts |
| Humana | Depends on plan | Frequently | Medical necessity documentation |
Key takeaway: Formularies are updated annually. Even if Wegovy was covered last plan year, renewal season can bring new prior authorization requirements or documentation requests.
Commercial Insurance vs Medicare Approval Workflow
The approval pathway differs depending on whether you have employer-sponsored insurance, an ACA Marketplace plan, Medicare Part D, or Medicaid.
Prescription Written
Healthcare provider writes the prescription for Wegovy
Insurance reviews Claim
Pharmacy submits claim; insurer reviews coverage rules
Prior Authorization?
Checks if drug requires PA approval
BMI/Comorbidity Check
Confirms BMI ≥30 or ≥27 with condition
Medical Review
Reviewer evaluates weight history and records
Indication Check
Confirms cardiovascular risk reduction use, not weight loss alone
Prior Authorization?
Checks clinical criteria for covered indication
Medical Review
Reviewer checks cardiovascular disease diagnosis
Approval or Denial
Coverage decision is issued by the insurer
Appeal (If Denied)
Submit additional evidence supporting medical necessity
| Coverage Type | Prior Authorization | Appeals | Savings Card Eligible |
|---|---|---|---|
| Employer Insurance | Often | Yes | Yes |
| Marketplace Plans | Often | Yes | Usually |
| Medicare Part D | Frequently | Yes | No |
| Medicaid | Usually | Yes | No |
Novo Nordisk Savings Card Eligibility
If your Wegovy prescription is approved through eligible commercial insurance, you may qualify for the Novo Nordisk Savings Card. This manufacturer program can reduce out-of-pocket costs for eligible patients, but it is not available to everyone.
| Eligible | Not Eligible |
|---|---|
| Commercial insurance | Medicare Part D |
| Employer-sponsored insurance | Medicaid |
| Marketplace plans (when eligible) | TRICARE |
| Private health insurance | VA Health Benefits |
Savings card terms, eligibility rules and maximum annual benefits may change. The program is intended for eligible commercially insured patients and cannot generally be combined with federal healthcare programs.
Example of a Successful Prior Authorization Submission
Reviewers evaluate whether submitted information supports medical necessity under the plan's weight-management drug policy. The example below illustrates common documentation in a successful request.
| Field | Example |
|---|---|
| Diagnosis | Obesity, BMI 33.4 |
| ICD-10 Code | E66.9 |
| Medication Requested | Wegovy 0.25 mg weekly (starting dose) |
| Comorbidity | Hypertension (I10) |
| Prior Attempt | 6-month documented diet and exercise program |
| Treatment Outcome | Insufficient weight loss with lifestyle measures alone |
| Supporting Documents | Office notes, weight log, comorbidity diagnosis |
Common ICD-10 Codes Used During Prior Authorization
Diagnosis codes help insurers identify why Wegovy has been prescribed. These codes alone don't guarantee approval, but they're a standard part of nearly every submission.
| ICD-10 Code | Condition |
|---|---|
| E66.9 | Obesity, unspecified |
| E66.01 | Morbid (severe) obesity due to excess calories |
| I10 | Essential (primary) hypertension |
| E78.5 | Hyperlipidemia, unspecified |
| I25.10 | Atherosclerotic heart disease (used for Medicare cardiovascular pathway) |
Understanding Insurance Terms You'll See During Prior Authorization
Insurers use consistent technical terminology throughout the review process. Knowing what these terms mean makes denial letters and pharmacy notifications easier to interpret.
| Term | Meaning | Why It Matters |
|---|---|---|
| Prior Authorization | Insurance approval required before coverage begins. | Required before nearly every Wegovy prescription can be filled. |
| Formulary | The insurer's list of covered medications. | Determines whether Wegovy is preferred, non-preferred or excluded. |
| Step Therapy | Requirement to try another approach first. | Often involves diet/exercise documentation or another medication. |
| Quantity Limit | Maximum amount covered during a specific period. | Usually limits Wegovy to one carton every 28 days. |
| Weight-Loss Drug Exclusion | A plan-level exclusion of the entire drug category. | Can block coverage regardless of clinical documentation. |
| Medical Necessity | Clinical justification explaining why treatment is appropriate. | One of the most important parts of every prior authorization. |
How Medicaid Coverage Can Differ by State
Medicaid is administered by individual states within federal guidelines, so Wegovy coverage requirements vary considerably depending on where you live. Many states still exclude weight-loss drugs from their preferred drug lists entirely.
| State Program | Prior Authorization | Notes |
|---|---|---|
| California Medicaid (Medi-Cal) | Common | Coverage depends on BMI documentation and state formulary. |
| Texas Medicaid | Common | Weight-loss drug coverage varies by managed care plan. |
| Florida Medicaid | Common | Prior authorization frequently required. |
| New York Medicaid | Plan Dependent | Coverage policies updated periodically. |
| Pennsylvania Medicaid | Common | Medical necessity documentation often required. |
Patients moving between states should expect a completely new coverage review, since preferred drug lists and clinical criteria for weight-management medications differ significantly by state Medicaid program.
2026 Formulary Trends Affecting Wegovy Coverage
Demand for GLP-1 weight-management medications continues to grow, and insurers have adjusted their formularies and review processes accordingly throughout 2026.
- More commercial plans require electronic prior authorization submissions for GLP-1 weight-loss drugs.
- BMI and weight-history documentation is reviewed more closely than in prior years.
- Renewal reviews increasingly require documented weight-loss progress to continue coverage.
- More employer plans are adding explicit weight-loss drug exclusions to control costs.
- Medicare Part D plans continue to limit coverage to the cardiovascular risk-reduction indication.
Realistic Reasons Prior Authorizations Get Approved
Many patients assume approval depends solely on BMI. In reality, reviewers weigh the complete clinical picture, including documented history and prior attempts, before making a decision.
| Strong Approval Factors | Why They Help |
|---|---|
| BMI clearly documented at 30+ (or 27+ with comorbidity) | Matches FDA-approved indication. |
| Multiple weight measurements over time | Demonstrates a chronic condition, not a single reading. |
| Documented diet/exercise or medication attempt | Satisfies common step therapy requirements. |
| Comorbidity diagnosis codes included | Strengthens medical necessity. |
| Detailed provider notes | Supports the overall clinical narrative. |
| No missing documentation | Reduces review delays. |
Common Mistakes That Delay Approval
- □ Prescription submitted before BMI documentation is available.
- □ Incorrect diagnosis code.
- □ Missing weight history over time.
- □ Missing diet/exercise or prior medication documentation.
- □ Missing provider signature.
- □ Wrong insurance member identification number.
- □ Comorbidity not documented when BMI is under 30.
- □ Requested dose doesn't match the titration schedule.
- □ Pharmacy and provider using different insurance information.
- □ Appeal submitted without additional supporting evidence.
Many of these issues are administrative rather than clinical. Resolving missing paperwork often leads to faster decisions without requiring a formal appeal.
Quick Checklist Before Your Provider Submits Prior Authorization
Reviewing this checklist before submission can help reduce delays and improve the likelihood of a complete application.
| Checklist Item | Status |
|---|---|
| BMI calculated and documented | ☐ |
| Weight history over multiple visits available | ☐ |
| Comorbidity diagnosis documented (if BMI under 30) | ☐ |
| Diet/exercise or prior medication attempt documented | ☐ |
| Office notes attached | ☐ |
| Provider signature completed | ☐ |
| Correct insurance information verified | ☐ |
| Requested Wegovy dose matches titration schedule | ☐ |
Sample Appeal Letter Following a Wegovy Denial
When a prior authorization is denied, healthcare providers often submit a letter of medical necessity explaining why Wegovy is clinically appropriate. The example below illustrates the structure commonly used.
Date Prior Authorization Department Re: Appeal for Wegovy Coverage The patient has a BMI of 33.4, classified as obesity, with a documented diagnosis of hypertension. Despite a supervised 6-month diet and exercise program, the patient's weight and associated comorbidity have not improved sufficiently. Based on the patient's BMI, weight history, comorbidity status and current clinical presentation, Wegovy is medically necessary to support sustained weight reduction and reduce obesity-related health risks. Attached are: • Office visit notes • Weight history and BMI calculations • Comorbidity diagnosis documentation • Prior authorization denial notice Thank you for your reconsideration.
Appeals supported by detailed weight history and comorbidity documentation are generally stronger than those that simply request reconsideration without additional evidence.
Bottom Line
Prior authorization for Wegovy exists primarily to confirm that your BMI, health history, and prior treatment attempts meet your plan's specific clinical policy for weight-management drugs, not to judge whether Wegovy is the right medication for you. Most approvals come down to complete documentation and clearly demonstrated medical necessity.
If your initial request is denied, many patients still obtain coverage through an appeal, additional documentation, or by exploring the Medicare cardiovascular risk-reduction pathway where applicable. Working closely with your healthcare provider and understanding your plan's specific requirements can significantly improve your chances of approval.
Frequently Asked Questions
Often, yes. Most plans approve Wegovy for a BMI of 30 or higher without requiring an additional comorbidity. A comorbidity such as hypertension, type 2 diabetes, or high cholesterol typically becomes necessary only when BMI falls between 27 and 29.9.
Most insurers require a BMI of 30 or higher, or a BMI of 27 or higher combined with a weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. Exact thresholds vary by plan.
Medicare Part D does not cover Wegovy when it's prescribed for weight loss alone. Many Part D plans do cover it when prescribed to reduce cardiovascular risk in patients who have established heart disease, since that is a separate FDA-approved indication.
Healthcare providers cannot override an insurer's decision, but they can submit an appeal with additional documentation, such as updated weight history or a comorbidity diagnosis, supporting medical necessity.
Most pharmacies notify your healthcare provider that prior authorization is required, but the prescribing provider typically completes and submits the authorization paperwork.
Yes. Many plans require renewal, often tied to documented weight-loss progress at 3, 6, or 12 month intervals after starting therapy.
Your healthcare provider, pharmacy or insurance company can usually provide status updates while the request is under review.
Some employer-sponsored plans exclude weight-management medications entirely, regardless of BMI or documentation. In this case, prior authorization won't help, since the exclusion applies at the plan-design level. Check your summary of benefits or ask your HR department directly.
Obesity medicine specialists and endocrinologists often provide detailed clinical documentation that may strengthen a prior authorization request, although approval still depends on your specific plan's criteria.
Yes. Prior authorization approvals generally do not transfer between insurance plans. A new insurer typically requires a completely new review.
No. Most plans that cover Wegovy require prior authorization, but a small number of formularies provide coverage without it depending on benefit design.
Many insurers issue decisions within several business days for electronic submissions, though manual reviews, incomplete documentation, or appeals can take longer.
Approval difficulty depends more on your specific plan's formulary placement than on the drug itself. Some plans prefer Wegovy, others prefer Zepbound, and coverage can change from year to year as manufacturer rebate agreements shift.
Depending on your insurance plan, you may have additional appeal rights, or your healthcare provider may recommend an alternative weight-management medication covered under your formulary.
How We Researched This Guide
Medical References
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information.
- Centers for Medicare & Medicaid Services. Medicare Part D Prescription Drug Benefit Guidance for Anti-Obesity Medications.
- American Heart Association / American College of Cardiology. Guidance on Cardiovascular Risk Reduction.
- Novo Nordisk. Wegovy Patient Savings Program and Patient Assistance Resources.
- National Council for Prescription Drug Programs (NCPDP). Electronic Prior Authorization Standards.
Related Resources
- Complete Prior Authorization Guide (2026)
- Ozempic Prior Authorization Requirements
- How to Appeal a Prescription Denial
- Ozempic for Weight Loss
- Medicare GLP-1 Bridge Program
Editorial Policy: Refill Relay medical content is researched using FDA prescribing information, Medicare and commercial insurance formularies, manufacturer patient support resources and peer-reviewed clinical guidance. Every article is reviewed for clarity, accuracy and usefulness before publication.